1-[4-(2-morpholinoethoxy)benzyl]naphthalen-2-ol | 1335047-84-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-[4-(2-morpholinoethoxy)benzyl]naphthalen-2-ol
• 英文别名: 1-{4-(2-morpholinoethoxy)benzyl}naphthalen-2-ol；1-[[4-(2-Morpholin-4-ylethoxy)phenyl]methyl]naphthalen-2-ol
• CAS: 1335047-84-1
• 化学式: C₂₃H₂₅NO₃
• 分子量: 363.456
• InChiKey: YNORISHGHIYNJN-UHFFFAOYSA-N

物化性质

• 熔点：
  129-132 °C
• 沸点：
  563.1±50.0 °C(Predicted)
• 密度：
  1.185±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  41.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-[4-(2-morpholinoethoxy)benzyl]naphthalen-2-ol 在 盐酸 作用下， 以 乙醚 为溶剂， 生成
  参考文献：
  名称：

  Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators

  摘要：

  In an systematic attempt to develop novel Selective Estrogen Receptor Modulators (SERMs), chiral 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2-hydroxynaphthalen-1-yl)methyl)piperidin-4-ols were designed based on an accepted pharmacophore model. Simpler prototypes, viz. racemic 1-((2-hydroxynaphthalen-1-yl)arylmethyl)piperidin-4-ols, were first synthesized to develop kinetic resolution to pure enantiomers. Simultaneously, a series of racemic 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2-hydroxynaphthalen-1-yl) methyl)piperidin-4-ols were evaluated against estrogen-responsive human MCF-7 breast cancer cells, but the compounds were found to be moderately active. The lack of potency could be due to the molecular bulk resulting in inadequate fit at the receptor. Subsequently, the molecular motif was modified to achiral 1-(4-(2-(dialkylamino)ethoxy)benzyl)naphthalen-2-ols by removing the piperidinol moiety. Bioevaluation of this new series of compounds displayed significantly enhanced cytotoxicity against MCF-7 cells. A representative compound for this series showed estrogen receptor alpha binding activity and the action is that of an antagonist. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.05.054
• 作为产物：
  描述：

  4-(2-吗啉乙氧基)苯甲醛 在 sodium tetrahydroborate 、 三氟化硼乙醚 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 1-[4-(2-morpholinoethoxy)benzyl]naphthalen-2-ol
  参考文献：
  名称：

  Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators

  摘要：

  In an systematic attempt to develop novel Selective Estrogen Receptor Modulators (SERMs), chiral 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2-hydroxynaphthalen-1-yl)methyl)piperidin-4-ols were designed based on an accepted pharmacophore model. Simpler prototypes, viz. racemic 1-((2-hydroxynaphthalen-1-yl)arylmethyl)piperidin-4-ols, were first synthesized to develop kinetic resolution to pure enantiomers. Simultaneously, a series of racemic 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2-hydroxynaphthalen-1-yl) methyl)piperidin-4-ols were evaluated against estrogen-responsive human MCF-7 breast cancer cells, but the compounds were found to be moderately active. The lack of potency could be due to the molecular bulk resulting in inadequate fit at the receptor. Subsequently, the molecular motif was modified to achiral 1-(4-(2-(dialkylamino)ethoxy)benzyl)naphthalen-2-ols by removing the piperidinol moiety. Bioevaluation of this new series of compounds displayed significantly enhanced cytotoxicity against MCF-7 cells. A representative compound for this series showed estrogen receptor alpha binding activity and the action is that of an antagonist. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.05.054

文献信息

• [EN] SELECTIVE ESTROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS SÉLECTIFS DES RÉCEPTEURS DES OESTROGÈNES
  申请人：UNIV DALHOUSIE

  公开号：WO2012079154A1

  公开（公告）日：2012-06-21

  The invention provides compounds of Formula (I) : wherein R1 is hydrogen, OH, halo, -CN, -NO2, -N=0, -NHOQ2, -OQ2, -SOQ2, -SO2Q2, -SON(Q2)2, - SO2N(Q2)2, -N(Q2)2, -C(O)OQ2, -C(O)Q2, -C(O)N(Q2)2, -C(=NQ2)NQ2, -NQ2C(=NQ2)NQ2, - C(O)N(Q2)(OQ2), -N(Q2)C(O)-Q2, -N(Q2)C(O)N(Q2)2, -N(Q2)C(O)O-Q2, -N(Q2)SO2Q2, -N(Q2)SOQ2, aliphatic, alkoxy, cycloaliphatic, aryl, arylalkyl, heterocyclic, or heteroaryl ring, each aliphatic, alkoxy, cycloaliphatic, aryl, arylalkyl, heterocyclic, and heteroaryl ring optionally including 1-3 substituents independently selected Q3; R2 and R3 are each independently hydrogen, OH, oxo, aliphatic, cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, optionally substituted with 1-3 of Q1 or Q2; X is a branched or straight C1-12 aliphatic chain wherein up to two carbon units are optionally and independently replaced by -C(Q1)2-, -C(Q2)2-, CHQ1, CHQ2-, -CO-, -CS-, -CONQ2, -CO2-, -OCO-, -NQ2-, -NQ2CO2-, - O-, -NQ2CONQ2-, -OCONQ2-, -NQ2CO-, -S-, -SO-, -SO2-, -SO2NQ2-, -NQ2SO2-, or -NQ2SO2NQ2-; G and G1 are each independently a branched or straight C1-2 aliphatic chain, or heterocycloalkyl, wherein up to two carbon units are optionally and independently replaced by -C(Q1)2-, -C(Q2)2-, CHQ1, CHQ2-, -CO-, - CS-, -CONQ2, -CO2-, -OCO-, -NQ2-, -NQ2CO2-, -O-, -NQ2CONQ2-, -OCONQ2-, -NQ2CO-, -S-, -SO-, - SO2-, -SO2NQ2-, -NQ2SO2-, or -NQ2SO2NQ2-, and pharmaceutically acceptable salts, solvates or prodaigs thereof, as well as methods of treating estrogen receptor mediated diseases and disorders using the compounds of Formula (I).

  该发明提供了Formula (I)的化合物：其中R1是氢、OH、卤素、-CN、-NO2、-N=0、-NHOQ2、-OQ2、-SOQ2、-SO2Q2、-SON(Q2)2、-SO2N(Q2)2、-N(Q2)2、-C(O)OQ2、-C(O)Q2、-C(O)N(Q2)2、-C(=NQ2)NQ2、-NQ2C(=NQ2)NQ2、-C(O)N(Q2)(OQ2)、-N(Q2)C(O)-Q2、-N(Q2)C(O)N(Q2)2、-N(Q2)C(O)O-Q2、-N(Q2)SO2Q2、-N(Q2)SOQ2、脂肪族、烷氧基、环脂肪族、芳基、芳基烷基、杂环、或杂芳基环，每个脂肪族、烷氧基、环脂肪族、芳基、芳基烷基、杂环和杂芳基环可选地包括1-3个独立选择的Q3取代基；R2和R3分别独立地是氢、OH、氧化物、脂肪族、环脂肪族、杂环脂肪族、芳基或杂芳基，可选地取代为1-3个Q1或Q2；X是分支或直链C1-12脂肪链，其中最多两个碳单位可选地和独立地被-C(Q1)2-、-C(Q2)2-、CHQ1、CHQ2-、-CO-、-CS-、-CONQ2、-CO2-、-OCO-、-NQ2-、-NQ2CO2-、-O-、-NQ2CONQ2-、-OCONQ2-、-NQ2CO-、-S-、-SO-、-SO2-、-SO2NQ2-、-NQ2SO2-或-NQ2SO2NQ2-取代；G和G1分别独立地是分支或直链C1-2脂肪链，或杂环脂肪族，其中最多两个碳单位可选地和独立地被-C(Q1)2-、-C(Q2)2-、CHQ1、CHQ2-、-CO-、-CS-、-CONQ2、-CO2-、-OCO-、-NQ2-、-NQ2CO2-、-O-、-NQ2CONQ2-、-OCONQ2-、-NQ2CO-、-S-、-SO-、-SO2-、-SO2NQ2-、-NQ2SO2-或-NQ2SO2NQ2-取代；以及药学上可接受的盐、溶剂或其制品，以及使用Formula (I)的化合物治疗雌激素受体介导的疾病和疾病的方法。
• Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators
  作者：Yogesh Yadav、Erin D. MacLean、Annyt Bhattacharyya、Virinder S. Parmar、Jan Balzarini、Christopher J. Barden、Catherine K.L. Too、Amitabh Jha

  DOI：10.1016/j.ejmech.2011.05.054

  日期：2011.9

  In an systematic attempt to develop novel Selective Estrogen Receptor Modulators (SERMs), chiral 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2-hydroxynaphthalen-1-yl)methyl)piperidin-4-ols were designed based on an accepted pharmacophore model. Simpler prototypes, viz. racemic 1-((2-hydroxynaphthalen-1-yl)arylmethyl)piperidin-4-ols, were first synthesized to develop kinetic resolution to pure enantiomers. Simultaneously, a series of racemic 1-((4-(2-(dialkylamino)ethoxy)phenyl)(2-hydroxynaphthalen-1-yl) methyl)piperidin-4-ols were evaluated against estrogen-responsive human MCF-7 breast cancer cells, but the compounds were found to be moderately active. The lack of potency could be due to the molecular bulk resulting in inadequate fit at the receptor. Subsequently, the molecular motif was modified to achiral 1-(4-(2-(dialkylamino)ethoxy)benzyl)naphthalen-2-ols by removing the piperidinol moiety. Bioevaluation of this new series of compounds displayed significantly enhanced cytotoxicity against MCF-7 cells. A representative compound for this series showed estrogen receptor alpha binding activity and the action is that of an antagonist. (C) 2011 Elsevier Masson SAS. All rights reserved.